Gland Pharma Ltd
Gland Pharma Ltd (GLAND)

Gland Pharma Ltd (GLAND)


Key Stats

Day's Price Range
52-Week Price Range
1 Month Return-16.54 %
3 Month Return-21.3 %
1 Year Return-43.88 %

Company Financials

  • Quarterly
  • Annual
Value in ₹ crore

Peer Comparsion

Rank 15
Rank 10
Rank 9
Dividend Yield
Rank 33
Rank 17
Price To Book Ratio
Rank 15
Debt To Asset
Rank 38

Company Information

Gland Pharma Ltd was incorporated as Gland Pharma Private Limited a private limited company under the Companies Act 1956 on March 20 1978 and was granted the certificate of incorporation by Registrar of Companies Andhra Pradesh at Hyderabad. Subsequently the name of the Company was changed to Gland Pharma Limited pursuant to a special resolution passed by the shareholders of the Company on December 5 1994 and a fresh certificate of incorporation dated April 25 1995 was issued by the Registrar of Companies Andhra Pradesh at Hyderabad consequent upon change of name and conversion into a public limited company under the Companies Act 1956. The company is primarily engaged in manufacturing injectable formulations.The company is one of the fastest growing generic injectablesfocused companies by revenue in the United States from 2014 to 2019. The company has 8 manufacturing facilities in India comprising four finished formulations facilities with a total of 23 production lines and three API facilities. The company sells products primarily under a business to business B2B model in over 60 countries as of March 31 2022 including the United States Europe Canada Australia India and the Rest of the world. The company has a consistent compliance track record with a range of regulatory regimes across these markets. The company also have an extensive track record in complex injectables development manufacturing and marketing and a close understanding of the related sophisticated scientific technical and regulatory processes. The company has expanded it nature of business from liquid parenterals to cover other elements of the injectables value chain including contract development own development dossier preparation and filing technology transfer and manufacturing across a range of delivery systems. Over the years the company has made substantial investments in the companies manufacturing infrastructure to support the product portfolio needs and reach. The company has seven manufacturing facilities in India comprising four finished formulations facilities with a total of 22 production lines and three API facilities. The companies API facilities provide with inhouse manufacturing capabilities for critical APIs enabling the company to control costs and quality and mitigate supply chain related risks around the key products. The companies capabilities as a vertically integrated company include internal research and development RD expertise robust manufacturing capabilities a strict quality assurance system extensive regulatory experience and established marketing and distribution relationships.As of March 31 2020 the company along with partners had 265 ANDA filings in the United States of which 204 were approved and 61 were pending approval. The 265 ANDA filings comprise 189 ANDA filings for sterile injectables 50 for oncology and 26 for ophthalmics related products. Out of these 265 ANDA filings 100 represent ANDAs owned by the company of which 63 ANDA filings are approved and 37 are pending approval. As of the same date the company along with partners had a total of 1415 product registrations comprising 368 product registrations in the United States Europe Canada and Australia 54 in India and 993 in the Rest of the world. The company also has a consistent regulatory compliance track record and all the facilities are approved by the USFDA from whom the company have had no warning letters since the inception of each facility. Other key regulatory agencies for which certain of our facilities have approvals include MHRA UK TGA Australia ANVISA Brazil AGES Austria and BGV Hamburg Germany.During the year 202021 the Company has incorporated Gland Pharma International Pte. Ltd. a Whollyowned Subsidiary in Singapore. It has incurred capital expenditure of Rs. 2287.76 million at its manufacturing facilities at Dundigal Pashamylaram VSEZ and Pharmacity. It has issued and allotted 8333333 fully paidup equity shares in the Initial Public Offer during November 2020.During FY 2022 the Company launched 47 product SKUs of 28 molecules like Micafungin Ziprasidone Bivalirudin RTU and Olapatadine Ophthalmic OTC. As of March 31 2022 it along with the partners had 284 ANDA filings in the US of which 234 were approved and 50 were pending approval. Out of these 115 were owned by the Company with 85 approvals and 30 pending for approval. It had manufacturing capacity for finished formulations of approximately 767 million units per annum. It filed 21 ANDAs 5 DMFs and received 32 ANDA approvals. It signed an agreement to supply upto 252 million doses of RDIFs Sputnik V COVID19 vaccine. It also entered into an agreement for purchase of RD and manufacturing facility of Vitane Biologics a biopharmaceutical company located in Hyderabad.
OrganisationGland Pharma Ltd